Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Retinoic acid-containing remedy for diabetes

A technology for retinoic acid and diabetes, applied in the field of anti-diabetic drugs, can solve the problems of diabetic coma, inability to adequately control blood sugar levels, etc., and achieve the effect of improving functions

Inactive Publication Date: 2007-02-28
JAPAN SCI & TECH CORP
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] These oral medications are effective in patients who maintain insulin secretion, but are not effective in patients with type 1 diabetes, for whom insulin secretion is insufficient and insulin injections to suppress blood sugar levels are essential
Even patients with type 2 diabetes sometimes require insulin injections: Insufficient control of blood sugar levels by diet and exercise and oral medications, severe infectious disease (such as complicated by severe pneumonia), the patient is undergoing surgery, complicated by severe kidney disease or severe liver disease or the patient is in a diabetic coma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Retinoic acid-containing remedy for diabetes
  • Retinoic acid-containing remedy for diabetes
  • Retinoic acid-containing remedy for diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Preparation of Retinoic Acid Pharmaceutical Preparations

[0050] As retinoic acid, commercially available retinoic acid (solid particles) was used as it was.

[0051] (1) Preparation of retinoic acid-inorganic substance composite particles

[0052] 13.6 mg of retinoic acid was dissolved in 900 μL of ethanol (or methanol), and 100 μL of 0.5 N NaOH aqueous solution was added to the solution. At this point, the pH is 7-7.5. As a mother solution, 100 µL of this solution was collected, added to 100 µL of distilled water containing Tween 80 (trade name), and the mixture was stirred well. After about 30 minutes, a 5M aqueous solution of calcium chloride was added and the mixture was stirred. After 30 minutes, an aqueous solution containing 1M sodium carbonate was added, and the mixture was further stirred. After continuous stirring for 24 hours, the resulting solution was freeze-dried overnight to obtain the desired retinoic acid-calcium carbonate composite particles.

...

Embodiment 2

[0057] The injection solution prepared in Example 1 (containing 6 mg of retinoic acid) was subcutaneously injected into the back of each diabetic rat at a dose of 1 mL through a syringe equipped with a 18-21 gauge needle. When using an 18-gauge needle, the injection site should be closed with surgical Aron Alpha (trade name) after injection to prevent leakage of the drug solution.

[0058] Subsequently, the change in body weight of each rat was observed, and the results are shown in FIG. 1 . As can be seen from Figure 1, the body weight of the control rats (D) not administered retinoic acid gradually decreased. Meanwhile, in the retinoic acid-administered rats (A) to (C), a decrease in body weight was observed at the initial stage, but a tendency to increase body weight was observed thereafter. In particular, the body weight of rats (C) administered with the pharmaceutical preparation of retinoic acid-organic substance composite particles decreased in a short period of time a...

Embodiment 3

[0062] Body weight changes of diabetic rats administered retinoic acid-organic substance (PLGA) composite particles (6 mg) and control diabetic rats (no retinoic acid administered) up to about 40 days are shown in Figure 3(a). The change of plasma insulin concentration and the change of blood glucose concentration of rats during the period are shown in Figs. 3(b) and 3(c). In the figure, ● represents a rat administered with retinoic acid-organic substance (PLGA) composite particles (6 mg), and ■ represents a control rat (retinoic acid was not administered).

[0063] In control rats not given retinoic acid, a trend was observed, with no change or gradual decrease in plasma insulin concentration, whereas in rats given retinoic acid-organic substance composite particles (LA / PLGA), plasma insulin concentration It was lowest around day 15 and then increased (Fig. 3(b)).

[0064]Further, Fig. 3(c) shows the change of blood glucose concentration, since the data was measured in the c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The present invention aims to provide a novel agent for treating and / or preventing diabetes which agent can not only control a blood sugar level but also fundamentally treat a patient with type I diabetes suffering from destruction of cells and a patient with type II diabetes suffering from dysfunction in insulin secretion. The present invention provides an agent for treating and / or preventing diabetes, the agent containing retinoic acid as an active ingredient. Retinoic acid incorporated as an active ingredient may be all-trans retinoic acid, an isomer thereof, a derivative thereof, a salt thereof or a prodrug thereof. Retinoic acid may be incorporated singly. Alternatively, composite particles of retinoic acid and an appropriate inorganic or organic substance are prepared, and the retinoic acid composite particles may be incorporated.

Description

technical field [0001] The present invention relates to a medicament for preventing and / or treating diabetes or its related diseases, which contains retinoic acid as an active ingredient. More particularly, the present invention relates to an antidiabetic drug that not only controls blood sugar levels but also acts directly on beta cells of the pancreas. Background technique [0002] It is said that there are about 6,000,000 diabetic patients in our country at present, and statistics show that, in particular, one tenth of people over 40 years old suffer from diabetes. Diabetes is defined as "a group of metabolic diseases having the main symptom of chronic hyperglycemia caused by insulin function deficiency" (Japanese Diabetes Association, Committee Report on Classification and Diagnostic Criteria of Diabetes, 1999). Diabetes is mainly divided into two types. Type 1 diabetes is caused by insufficient insulin due to the destruction of insulin-secreting β cells of the pancreas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/203A61P9/10A61P3/10
CPCA61K31/203A61P3/10A61P5/50A61P9/10A61P43/00
Inventor 山口叶子五十岚理慧
Owner JAPAN SCI & TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com